BB Biotech – executive interview

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Oil & Gas

Real Estate

TMT

Pharnext

MCap

EUR1m

Last close

EUR0.10

▲ 0.06 (150.00%)

Actinogen Medical

MCap

AUD48m

Last close

AUD0.03

▲ 0.01 (50.00%)

DFR Gold

MCap

CAD13m

Last close

CAD0.10

▲ 0.03 (42.86%)
Sectors
Sectors
Investment Strategy
Investment Strategy
View All

Latest
Thematics
Thematics
View All Thematics

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

James Brotherton Financial Director — Tyman
Equity Research
Investor Relations
Contact us

BB Biotech – executive interview

Associated equity: BB Biotech

BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but managed on a bottom-up basis, with a focused c 20–35 stock portfolio.

View this company

BB Biotech — 4 videos in collection

In this interview, we speak to Dr Daniel Koller, portfolio manager at BB Biotech (BION), the Swiss-based investment company listed in Switzerland, Germany and Italy. Dr Koller shares his views on the biotech sector and expands on the following themes:

The sectors ability to outperform the broader equity market as the market moves forward and returns to growth.
The outlook and key risks for the biotech/pharma sector for the remainder of 2023.
Listed versus private companies valuations in the sector.
How BB Biotech is positioned to take advantage of the current situation in the market amid lower valuations.

< Previous

Next >

You may also be interested in these:

Investment Companies

07.09.22